Search results for "s lymphoma"

showing 10 items of 50 documents

MACOP-B chemotherapy for the treatment of high grade and intermediate grade non Hodgkin's lymphoma.

1990

Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone and bleomycin). Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. Four weeks after termination of therapy, 75% of patients with de novo NHL and 72% of the patients with relapsed NHL were in complete remission (CR). In the group of newly diagnosed NHL, 22% achieved partial remission (PR) and 3% no change (NC), whereas in the group wi…

AdultMalemedicine.medical_specialtyVincristineCyclophosphamidemedicine.medical_treatmentLeucovorinSalvage therapyGastroenterologyBleomycinimmune system diseaseshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIntermediate GradeCyclophosphamideAgedChemotherapybusiness.industryLymphoma Non-HodgkinHematologyGeneral MedicineMiddle Agedmedicine.diseaseNon-Hodgkin's lymphomaSurgeryLymphomaMethotrexateDoxorubicinVincristinePrednisoneFemaleNeoplasm Recurrence LocalbusinessProgressive diseasemedicine.drugBlut
researchProduct

Primary cutaneous lymphomas in children: A prospective study from the Spanish Academy of Dermatology and Venereology (AEDV) Primary Cutaneous Lymphom…

2021

Background/Objectives Primary cutaneous lymphomas are rare in pediatric patients. The clinical and histopathological manifestations may differ from those in adults. Due to their low frequency and the insidious clinical picture, the diagnosis is usually delayed. The Spanish Primary Cutaneous Lymphoma Registry was initiated in 2016 as a multicenter registry that would allow better insight into the epidemiological, clinical, histopathological, and treatment response characteristics of patients with primary cutaneous lymphomas. Methods We conducted a prospective observational cohort study of primary cutaneous lymphomas in pediatric patients participating in the Spanish Academy of Dermatology an…

AdultTreatment responsemedicine.medical_specialtyVenereologySkin NeoplasmsAdolescentlymphomaDermatologyMycosis FungoidesVenereologyEpidemiologymedicineneoplasms-malignantHumansProspective StudiesRegistriesProspective cohort studyChildtherapy-topicalMycosis fungoidesbusiness.industryPrimary cutaneous lymphomamedicine.diseaseDermatologyLymphomaPediatrics Perinatology and Child HealthbusinessphototherapyCohort studyPediatric dermatologyREFERENCES
researchProduct

Hodgkin's lymphoma of the thyroid in a woman with autoimmune thyroiditis

2015

Autoimmune thyroiditismedicine.anatomical_structurebusiness.industryImmunologyThyroidmedicineGeneral MedicineHodgkin's lymphomamedicine.diseasebusinessRevista Clínica Española
researchProduct

Are blood donors an adequate control group to ascertain HCV prevalence in non-Hodgkin’s lymphoma patients?

2002

Blood donorSettore MED/09 - Medicina Internanon-Hodgkin’s lymphomaHCV prevalence
researchProduct

Subcutaneous panniculitis-like T-cell lymphoma, lupus erythematosus profundus, and overlapping cases: molecular characterization through the study of…

2021

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare cytotoxic cutaneous lymphoma. Differential diagnosis with lupus erythematosus panniculitis (LEP) can be challenging and overlapping cases have been described. In this study, we investigate whether gene expression profiling may or not identify markers that can be used to improve our understanding of the disease and to make a precise differential diagnosis. SPTCL, LEP, and overlapping cases were analyzed using a customized NanoString platform including 208 genes related to T-cell differentiation, stromal signatures, oncogenes, and tumor suppressor genes. Gene expression unsupervised analysis of the samples differentiated SPTCL f…

Cancer ResearchPathologymedicine.medical_specialtyPanniculitiseducationBiologyLymphoma T-CellCutaneous lymphomaDiagnosis Differential03 medical and health sciences0302 clinical medicineSubcutaneous Panniculitis-Like T-Cell LymphomaPanniculitis Lupus ErythematosusmedicineHumansT-cell lymphomahealth care economics and organizationsLupus erythematosusHematologymedicine.diseaseImmunohistochemistryLymphomaGene expression profilingOncology030220 oncology & carcinogenesisDifferential diagnosishormones hormone substitutes and hormone antagonistsLupus erythematosus panniculitis030215 immunologyLeukemia & Lymphoma
researchProduct

Incidence, Medical Resource Utilisation and Costs of Hyperuricemia and Tumour Lysis Syndrome in Patients with Acute Leukaemia and Non-Hodgkin's Lymph…

2003

Hyperuricemia (HU) and tumour lysis syndrome (TLS) are complications of acute leukaemia and non-Hodgkin lymphoma (NHL) leading to increased morbidity and mortality. The objective of this study was to define incidence and calculate health care cost associated with HU and TLS. 788 acute leukaemia and NHL patients from Belgium, The Netherlands, Spain and UK were screened retrospectively for HU and TLS. Resource use related to HU and TLS was recorded and costs were calculated applying local unit costs. Results showed that HU occurred in 18.9% of patients, and 27.8% of them fulfilled TLS criteria. The cost of HU without TLS was 672 euros (SE 181), the cost of TLS 7,342 euros (SE 1,412). TLS requ…

Cancer Researchmedicine.medical_specialtyPediatricsmedicine.medical_treatmentHyperuricemiaRenal DialysisRisk FactorsIntensive caremedicineRasburicaseHumansHyperuricemiaChildhealth care economics and organizationsDialysisNetherlandsLeukemiabusiness.industryIncidenceLymphoma Non-HodgkinIncidence (epidemiology)Age FactorsDisease ManagementHealth Care CostsHematologyMiddle Agedmedicine.diseaseUnited KingdomLymphomaSurgeryNon-Hodgkin's lymphomaTumor lysis syndromeOncologySpainAcute DiseaseHealth ResourcesTumor Lysis Syndromebusinessmedicine.drugLeukemia & Lymphoma
researchProduct

Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32

2010

To identify susceptibility loci for non-Hodgkin lymphoma subtypes, we conducted a three-stage genome-wide association study. We identified two variants associated with follicular lymphoma at 6p21.32 (rs10484561, combined P = 1.12 × 10-29 and rs7755224, combined P = 2.00 × 10-19; r2 = 1.0), supporting the idea that major histocompatibility complex genetic variation influences follicular lymphoma susceptibility. We also found confirmatory evidence of a previously reported association between chronic lymphocytic leukemia/small lymphocytic lymphoma and rs735665 (combined P = 4.24 × 10-9). © 2010 Nature America, Inc. All rights reserved.

Chronic lymphocytic leukemiaFollicular lymphomaLocus (genetics)Genome-wide association studyHuman leukocyte antigenBiologyArticleMajor Histocompatibility Complex03 medical and health sciences0302 clinical medicinefollicular lymphomaRisk Factorshemic and lymphatic diseasesGeneticsmedicineHumansLymphoma Follicular030304 developmental biology0303 health sciencesLymphoma Non-HodgkinGenetic Variation16. Peace & justicemedicine.diseaseLeukemia Lymphocytic Chronic B-Cell3. Good healthLymphomaNon-Hodgkin's lymphomaLeukemia030220 oncology & carcinogenesisImmunologyDisease SusceptibilityGenome-Wide Association Study
researchProduct

Gene Expression Analysis Uncovers Similarity and Differences Among Burkitt Lymphoma Subtypes.

2011

Abstract Abstract 2494 Background. Burkitt lymphoma (BL) is currently listed in the WHO classification of lymphoid tumors as a single genetic and morphological entity with variation in clinical presentation. In particular, three clinical subsets of BL are recognized: endemic (eBL), sporadic (sBL) and immunodeficiency associated (ID-BL). Each affects different populations and can present with different features. So far, possible differences in their gene expression profiles (GEP) have not been investigated. In this study we aimed to 1) assess whether BL subtypes present with differences in their GEP; 2) investigate the relationship of the different BL subtypes with the non-neoplastic cellula…

Gene Expression Profiles; burkitt lymphomaGene expression analysieducationTransplantation HeterologousImmunologyMice NudeBiologyburkitt lymphomaBiochemistryBurkitt lymphoma.Micehemic and lymphatic diseasesCell Line TumormedicineAnimalsCluster AnalysisHumansRegulation of gene expressionGeneticsGene Expression ProfilesGENE EXPRESSION PROFILEMicroarray analysis techniquesGene Expression ProfilingGerminal centerCell BiologyHematologymedicine.diseaseMicroarray AnalysisPhenotypeLymphomaGene expression profilingTransplantationGene Expression Regulation NeoplasticPhenotypeBurkitt's lymphomaNeoplasm TransplantationGene expression analysis;Burkitt lymphoma.
researchProduct

Liver Involvement in Hodgkin's Lymphoma: Types of Injuries and Therapeutic Implications

2017

The hepatocytolysis raises questions on following therapeutic conduct when it occurs during chemotherapy for Hodgkin's lymphoma, expression of its liver toxicity. But the onset of primary liver Hodgkin's lymphoma, including the form manifested by acute liver failure, poses even greater problems, as in the case of occurrence of vanishing bile duct syndrome - expression of a paraneoplastic syndrome, hemophagocytic lymphohistiocytosis, peliosis hepatis or association of lymphoma with infection with hepatitis viruses or human immunodeficiency virus or different autoimmune diseases. This review summarizes the clinical experience acquired on the relationship between Hodgkin's lymphoma and liver, …

Hepatitismedicine.medical_specialtyPathologyChemotherapyHemophagocytic lymphohistiocytosisbusiness.industrymedicine.medical_treatmentVanishing bile duct syndromeJaundicemedicine.diseaseHodgkin's lymphomaGastroenterology03 medical and health sciences0302 clinical medicineimmune system diseaseshemic and lymphatic diseases030220 oncology & carcinogenesisInternal medicinemedicine030211 gastroenterology & hepatologyPeliosis hepatismedicine.symptomLiver dysfunctionbusinessInternational Journal of Pharmacology, Phytochemistry and Ethnomedicine
researchProduct

Bone marrow biopsy in Hodgkin's lymphoma.

2004

In the study of patients with Hodgkin's lymphoma (HL) the evaluation of bone marrow biopsy (BMB) can be difficult. In this review we analyze the main diagnostic features and the clinical risk factors of BM involvement. Although the role of BMB is criticized by some authors, its value is irreplaceable in the staging of HL and in the diagnosis of primary medullary HL. The Ann Arbor staging committee criteria should be revised and updated in the light of the current immunohistochemical studies that give a fundamental help in the diagnostic process. A single BMB should be adequate for diagnosis in most instances. In cases of suspicious involvement a controlateral BMB could be performed.

Hodgkin's lymphoma.Diagnosis DifferentialPractice Guidelines as TopicHumansBone marrowbiopsyBone Marrow ExaminationHodgkin DiseaseImmunophenotypingEuropean journal of haematology
researchProduct